Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
Condition(s):Relapsing Remitting Multiple SclerosisLast Updated:March 1, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsing Remitting Multiple SclerosisLast Updated:March 1, 2024Recruiting
Condition(s):Relapsing-Remitting Multiple SclerosisLast Updated:March 5, 2024Active, not recruiting
Condition(s):Relapsing Remitting Multiple SclerosisLast Updated:November 3, 2022Completed
Condition(s):Relapsing Remitting Multiple SclerosisLast Updated:December 28, 2015Withdrawn
Condition(s):Relapsing-remitting Multiple SclerosisLast Updated:June 18, 2023Not yet recruiting
Condition(s):Relapsing Remitting Multiple SclerosisLast Updated:February 5, 2024Completed
Condition(s):Relapsing-Remitting Multiple SclerosisLast Updated:March 15, 2024Recruiting
Condition(s):Relapsing Remitting Multiple SclerosisLast Updated:July 3, 2023Active, not recruiting
Condition(s):Relapsing Remitting Multiple SclerosisLast Updated:April 21, 2023Active, not recruiting
Condition(s):Relapsing Remitting Multiple SclerosisLast Updated:November 18, 2021Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.